利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

215 条记录 (耗时 0.026 秒)

    Swallowable capsule and method for stimulating incretin production within the intestinal tract
    2.
    发明授权
    Swallowable capsule and method for stimulating incretin production within the intestinal tract 有权

    公开(公告)号：US11872396B2

    公开(公告)日：2024-01-16

    申请号：US17885049

    申请日：2022-08-10

    申请人： InCube Labs, LLC

    发明人： Mir A. Imran ,  Mir Hashim ,  Emily Arnsdorf

    IPC分类号： A61N1/36 ,  A61N1/05 ,  A61K38/26 ,  A61N1/372 ,  A61N1/06

    CPC分类号： A61N1/36007 ,  A61K38/26 ,  A61N1/05 ,  A61N1/0507 ,  A61N1/0509 ,  A61N1/37217 ,  A61N1/06

    摘要： Embodiments of the invention provide apparatus and methods for stimulating L cells in the intestinal tract to produce incretins for the treatment of conditions including diabetes and obesity. Many embodiments provide a method and apparatus for the treatment of diabetes by electrically stimulating L-cells to secrete incretins to stimulate or otherwise modulate the production of insulin. Particular embodiments provide a swallowable capsule for stimulating L-cells in the intestinal tract as the capsule moves through the tract. The capsule can include two or more electrodes for providing electrical stimulation to L-cells, a power source for powering one or more components of the capsule, a sensor for sensing the location of the capsule in the intestinal tract; a controller and a waveform generator for generating the electrical signals emitted by the electrodes to stimulate the L-cells to secrete incretins such as GLP-1 to stimulate insulin production for glucose regulation of diabetic conditions.

    BIODEGRADABLE MEDICAL IMPLANTS, POLYMER COMPOSITIONS AND METHODS OF USE
    4.
    发明公开
    BIODEGRADABLE MEDICAL IMPLANTS, POLYMER COMPOSITIONS AND METHODS OF USE 审中-公开

    公开(公告)号：US20230226252A1

    公开(公告)日：2023-07-20

    申请号：US18188137

    申请日：2023-03-22

    申请人： InCube Labs, LLC

    发明人： Mir IMRAN ,  Sanjay PATEL ,  Joel HARRIS

    IPC分类号： A61F2/06 ,  A61L31/14 ,  A61L17/10

    CPC分类号： A61F2/06 ,  A61L31/148 ,  A61L17/10 ,  A61F2210/0004

    摘要： Embodiments of the invention provide compositions including bio degradable polymers, medical implants fabricated from these compositions and methods of using such implants. Many embodiments provide medical implants comprising a first polymer backbone having a first rate of biodegradation and a second polymer backbone having a second rate of biodegradation faster than the first rate. In some embodiments, the second backbone is configured to be replaced by a natural tissue layer. The first backbone provides a scaffold for the implant while the second backbone degrades. This scaffold can enhance mechanical properties of the implant including various aspects of mechanical strength such as tensile, bending, hoop and yield strength; and elasticity. The scaffold also serves to maintain a minimum level of structural support of the implant during the period of degradation of the second backbone or for the entire life of the implant so that the implant does not mechanically fail.

    Systems and methods for patient-enabled bladder control
    7.
    发明授权
    Systems and methods for patient-enabled bladder control 有权

    公开(公告)号：US11247050B2

    公开(公告)日：2022-02-15

    申请号：US16567342

    申请日：2019-09-11

    申请人： InCube Labs, LLC

    发明人： Mir Imran

    IPC分类号： A61N1/36 ,  A61N1/05 ,  A61N1/372

    摘要： A system for controlling urination in a patient includes an implantable controller and an external device. The implantable controller includes circuitry and electrodes for stimulating the pudenal nerves in order to control urination. In addition, the implantable controller includes sensors for determining information on bladder fullness and for transmitting such information to an external device which is used for controlling the implanted controller. The external device will display when bladder filling exceeds a safe threshold level, allowing the patient and a caregiver to take appropriate steps to allow the patient to urinate.

    Method for Treating Diabetes and Other Glucose Regulation Disorders Using Stem Cells
    8.
    发明申请
    Method for Treating Diabetes and Other Glucose Regulation Disorders Using Stem Cells 有权

    公开(公告)号：US20220008479A1

    公开(公告)日：2022-01-13

    申请号：US17363898

    申请日：2021-06-30

    申请人： INCUBE LABS, LLC

    发明人： Mir Imran

    IPC分类号： A61K35/38 ,  A61K35/28 ,  C12N5/071

    摘要： Various embodiments of the invention provide methods of treating diabetes and other glucose regulation disorders. In one embodiment, the method comprises removing L-cells from a donor, obtaining stem cells from a patient, and culturing the L-cells in the presence of the stem cells under conditions such that the stem cells differentiate into stem cell-derived L-cells (SCDLC). An amount of the SCDLC is introduced into the patient sufficient to cause a lowering of the patient's blood glucose level after ingestion of food. In another embodiment, the method comprises removing K-cells from a donor, obtaining stem cells from a patient, and culturing the K-cells in the presence of the stem cells under conditions such that the stem cells differentiate into stem cell-derived K-cells (SCDKC). An amount of the SCDKC is introduced into the patient sufficient to cause a lowering of the patient's blood glucose level after ingestion of food.

    Pharmaceutical compositions and methods for fabrication of solid masses comprising anti-interleukin antibodies
    9.
    发明授权
    Pharmaceutical compositions and methods for fabrication of solid masses comprising anti-interleukin antibodies 有权

    公开(公告)号：US10953075B2

    公开(公告)日：2021-03-23

    申请号：US16036590

    申请日：2018-07-16

    申请人： InCube Labs, LLC

    发明人： Mercedes Morales ,  Mir Imran ,  Radhika Korupolu ,  Mir Hashim

    IPC分类号： C07K16/00 ,  A61K38/28 ,  C07K16/24 ,  A61K9/20 ,  A61K38/26

    摘要： Embodiments of the invention provide shaped masses comprising one or more drugs such as proteins or polypeptides and methods for forming such shaped masses. One embodiment provides a shaped mass comprising a drug such as a protein or polypeptide having a biological activity in the body of a mammal. The shaped mass is formed by compression of a precursor material comprising the drug wherein an amount of biologically active drug in the mass is a preserved above a minimum level. Drugs which may be incorporated into the shaped mass may include one or more glucose regulating proteins such as insulin, incretins; and immunoglobulins such as TNF-inhibiting antibodies or interleukin neutralizing antibodies. Embodiments of the shaped mass may be incorporated into a tissue penetrating member which is inserted into the intestinal wall allowing for the oral delivery of proteins and peptides which would otherwise be degraded in the intestinal tract.